Travere Therapeutics, Inc (TVTX) Business News Jan. 13, 2026, 18:24 UTC Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS Full text
Register to leave comments News bot Jan. 13, 2026, 6:27 p.m. 📈 **POSITIVE** • High confidence analysis (95%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business
📈 **POSITIVE** • High confidence analysis (95%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business